Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
EyeGate reported data in its Ocular Bandage Gel (OBG) studies in punctate epitheliopathies (PE) and in corneal wound healing following bilateral photorefractive keratectomy (PRK) surgery. The PRK study showed improved wound healing and the PE trial showed improvement in patient symptoms. EyeGate will meet with the FDA to discuss whether the existing data are sufficient for a 510(k) de novo regulatory filing.
EyeGate Pharmaceuticals |
Positive signals in OBG PRK and PE studies
|
Pharma & biotech |
QuickView
19 November 2018 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
|
EyeGate reported data in its Ocular Bandage Gel (OBG) studies in punctate epitheliopathies (PE) and in corneal wound healing following bilateral photorefractive keratectomy (PRK) surgery. The PRK study showed improved wound healing and the PE trial showed improvement in patient symptoms. EyeGate will meet with the FDA to discuss whether the existing data are sufficient for a 510(k) de novo regulatory filing.
OBG shows improved wound healing
EyeGate’s OBG is a topical eye drop based on its proprietary cross-linked thiolated carboxymethyl-hyaluronic acid (CMHA-S). CMHA-S is believed to have hydrating and healing properties, and its crosslinking may help resist degradation. In the PRK study (n=45), two OBG dosing arms were compared to the current standard of care (SoC), a bandage contact lens (BCL) plus artificial tears. Both OBG arms outperformed the SoC; at day 3, 73% and 87% of eyes in the two OBG arms were healed vs 67% for SoC. At day 4, 100% in OBG treated eyes were healed vs 87% for SoC. There were no safety concerns observed in any group. These results follow a pilot bilateral PRK study (n=39) completed in Q117, which found that at day 3, 83% of those receiving OBG had complete wound closure vs 54% in SoC. All in, OBG is more convenient then SoC (since no BCL) and appears more effective.
PE study shows symptom improvement
In EyeGate’s PE study (n=30), subjects with PE (due to conditions such as dry eye) received either OBG or a commercially available lubricant drop. OBG showed a statistically significant reduction in symptoms at day 7 and 28 (but the result on day 14 was not reported), but there was no significant difference in total corneal staining reduction (26% for OBG vs 23% for lubricant arm) at day 7. Although the reduction in reported symptoms (days 7 and 28) are encouraging, the FDA will be ultimately assess whether the data on hand are sufficient to support clearance on treating PE symptoms. The PE market is much larger than wound healing, as c 30 million Americans have dry eye-related symptoms, vs up to 2-3 million corneal injuries per year in the US.
Valuation: EV of $10.7m; funding need by Q319
EyeGate had $9.9m cash at 30 September 2018. Its H118 net burn rate was $8.84m, and the firm estimates its cash on hand should be sufficient into Q419. A larger and longer study in PE may be needed to better assess the product’s applicability in PE, although the two PRK studies to date provide more robust suggestions of efficacy in the corneal wound healing indication. EyeGate will meet with the FDA to determine whether existing clinical data can support a 510(k) de novo regulatory filing. If not, the firm plans to start its next OBG study in H119.
EyeGate Pharmaceuticals is a client of Edison Investment Research Limited
|
Historical financials
Source: Company accounts |
|
Disclaimer
|
|
Disclaimer
|
Research: Financials
ICG-Longbow Senior Secured UK Property Debt Investments (LBOW) offers investors exposure to the UK real estate debt market, mainly through investments in senior secured whole loans. LBOW’s investment strategy is supported by the team’s deep expertise in both debt and UK real estate, enabling it to continue to pay a high stable dividend by investing in higher LTV loans, while controlling the risk through extensive analysis of the underlying properties’ cash flow generation potential, as well as the borrower’s business plan. The investment strategy should be assisted by the relatively favourable rental growth prospects in parts of the regional UK real estate market.